Dr. Roy Herbst
Scientific Advisory Board
M.D. Cornell University Medical College
Ph.D. Molecular cell biology, The Rockefeller University.
M.S. clinical translational research, Harvard University
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology at the Yale School of Medicine.
Chief of Medical Oncology at the Yale Cancer Center and Smilow Cancer Hospital, and Associate Cancer Center Director for Translational Science.
Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.
Dr. Herbst is a Fellow of the American Society of Clinical Oncology and a member of the American Association of Cancer Research (AACR), where he serves as an elected member of its board of directors and chairs the Tobacco Task Force. In 2019 he was elected to the International Association for the Study of Lung Cancer (IASLC) board of directors. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians.
Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center (UT-MDACC) in Houston, Texas.
He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program.
His work has led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have revolutionized the field and greatly enhanced patient survival. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients.
He has authored or co-authored more than 350 publications, including peer-reviewed journal articles, abstracts, and book chapters.
His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively.
